Nicholas Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Nicholas Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-46,541	Closed	-$2.83M	–	179
2019 Q4	$2.83M	Buy	46,541 +25,344	+120%	+$1.38M	0.29%	106
2019 Q3	$869K	Buy	21,197 +14,533	+218%	+$694K	0.07%	194
2019 Q2	$314K	Buy	+6,664	New	+$266K	0.03%	204
2018 Q4	–	Sell	-86,353	Closed	-$3.83M	–	223
2018 Q3	$3.83M	Sell	86,353 -280	-0.3%	-$14.7K	0.31%	128
2018 Q2	$5.09M	Buy	86,633 +6,143	+8%	+$350K	0.36%	80
2018 Q1	$3.68M	Buy	+80,490	New	+$3.32M	0.26%	126

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nicholas Investment Partners's CRSP Position: Q1 2020 in Review

Nicholas Investment Partners sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 46,541 shares — an estimated $2.83M sold.

Nicholas Investment Partners first reported a position in CRSP in Q1 2018 and held it in 6 quarters. The position peaked at $5.09M in Q2 2018. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

Nicholas Investment Partners reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
Nicholas Investment Partners sold 46,541 CRISPR Therapeutics shares in Q1 2020, an estimated $2.83M.
Nicholas Investment Partners first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 6 quarters.
Nicholas Investment Partners's CRISPR Therapeutics position peaked at $5.09M in Q2 2018.
257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Nicholas Investment Partners's 13F filing for Q1 2020, filed 13 May 2020.